Richard Barry, President and CEO of Filana Therapeutics, Inc., filed a Form 4 on November 19, 2026, disclosing a purchase of 132,926 shares of common stock on November 17, 2026.

Key Highlights

  • Reporting person: Richard Barry, identified in the filing as President and CEO and a Director of Filana Therapeutics, Inc.
  • Transaction: Purchase (transaction code P) of 132,926 shares of common stock on November 17, 2026.
  • Price per share: $0.48, as reported in the filing.
  • Post-transaction ownership: 1,911,096 shares of common stock beneficially owned following the transaction, held indirectly by trust.
  • Ownership form: The shares are held indirectly, with the nature of indirect beneficial ownership listed as "By Trust."
  • Filing signatory: The form was signed by Eric J. Schoen by Power of Attorney on November 19, 2026.

Barry Richard's Open-Market Purchase of Filana Therapeutics Common Stock

According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 19, 2026, Richard Barry, who serves as both President and CEO and a Director of Filana Therapeutics, Inc. (NASDAQ:FLNA), acquired 132,926 shares of the company's common stock on November 17, 2026, at a price of $0.48 per share. The transaction code reported is "P," indicating an open-market purchase.

The filing discloses that following this transaction, Barry holds 1,911,096 shares of Filana Therapeutics common stock beneficially. The ownership form is listed as indirect, with the nature of that indirect ownership described as "By Trust." No derivative securities transactions were reported in Table II of the filing.

The Form 4 was filed pursuant to Section 16(a) of the Securities Exchange Act of 1934. The form was executed by Eric J. Schoen acting by Power of Attorney on behalf of the reporting person. No amendment date was provided, indicating this is an original filing. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan, as the corresponding checkbox was not selected.

What Was Disclosed

The filing reports a single open-market purchase of 132,926 shares of Filana Therapeutics common stock by President and CEO Richard Barry on November 17, 2026, at $0.48 per share, resulting in indirect beneficial ownership of 1,911,096 shares held by trust.